BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22076492)

  • 1. Current treatment options for neuroendocrine tumors.
    Hörsch D; Grabowski P; Schneider CP; Petrovitch A; Kaemmerer D; Hommann M; Baum RP
    Drugs Today (Barc); 2011 Oct; 47(10):773-86. PubMed ID: 22076492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N; Reidy-Lagunes D
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK; Bergsland EK
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic neuroendocrine neoplasms.
    Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin.
    Auernhammer CJ; Göke B
    Gut; 2011 Jul; 60(7):1009-21. PubMed ID: 21378384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies for neuroendocrine liver metastases.
    Frilling A; Clift AK
    Cancer; 2015 Apr; 121(8):1172-86. PubMed ID: 25274401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving treatment strategies for management of carcinoid tumors.
    Strosberg J
    Curr Treat Options Oncol; 2013 Sep; 14(3):374-88. PubMed ID: 23892588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic neuroendocrine tumors.
    Muniraj T; Vignesh S; Shetty S; Thiruvengadam S; Aslanian HR
    Dis Mon; 2013 Jan; 59(1):5-19. PubMed ID: 23312533
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S; Saif MW
    Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG; Strosberg JR; Halfdanarson TR
    Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pulmonary neuroendocrine neoplasms].
    Sayeg Y; Sayeg M; Baum RP; Kulkarni HR; Presselt N; Mäder I; Kunze A; Sänger J; Hörsch D; Bonnet R
    Pneumologie; 2014 Jul; 68(7):456-77. PubMed ID: 25006841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
    Briest F; Grabowski P
    Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment strategies in advanced neuroendocrine tumours.
    Walter T; Brixi-Benmansour H; Lombard-Bohas C; Cadiot G
    Dig Liver Dis; 2012 Feb; 44(2):95-105. PubMed ID: 21983252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.